Literature DB >> 21997685

Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables.

Sabrina Rossi1, Rosalba Miceli, Luca Messerini, Italo Bearzi, Guido Mazzoleni, Carlo Capella, Gianluigi Arrigoni, Aurelio Sonzogni, Angelo Sidoni, Luisa Toffolatti, Licia Laurino, Luigi Mariani, Vincenza Vinaccia, Chiara Gnocchi, Alessandro Gronchi, Paolo G Casali, Angelo P Dei Tos.   

Abstract

Gastrointestinal stromal tumor (GIST) natural history per se has not been extensively investigated yet, with most data being drawn from large studies with a relevant referral bias. Hence, the estimation of prognosis still remains a critical issue. We retrospectively evaluated 929 GISTs resected between 1980 and 2000 in 35 Italian institutions. A total of 526 patients were found to be suitable for refining risk assessment through the development of a survival nomogram. Median follow-up was 126 months. On testing for potential prognostic parameters, age, tumor site, size, and mitotic index proved to be predictors of OS on both univariable and multivariable Cox model analyses, whereas necrosis and cytonuclear atypia were significant on univariable analysis only. The discriminative ability of the model, including the parameters selected after a backward procedure (C=0.72), improved compared with the National Institutes of Health 2002 (C=0.64) and the National Comprehensive Cancer Network 2007 (C=0.63). On the basis of these data we developed a prognostic nomogram for survival that considers site, size, and mitotic index as continuous variables, providing estimates stratified for patients aged ≤65 and >65 years. This nomogram is a tool based on survival. It overcomes problems that result from artificial categorization of continuous variables. We believe that in the future this should also be attempted by nomograms based on the risk of relapse.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997685     DOI: 10.1097/PAS.0b013e31822d63a7

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  48 in total

Review 1.  Adjuvant therapy of gastrointestinal stromal tumors (GIST).

Authors:  Paolo G Casali; Elena Fumagalli; Alessandro Gronchi
Journal:  Curr Treat Options Oncol       Date:  2012-09

2.  Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.

Authors:  Ronald P DeMatteo; Karla V Ballman; Cristina R Antonescu; Christopher Corless; Violetta Kolesnikova; Margaret von Mehren; Martin D McCarter; Jeffrey Norton; Robert G Maki; Peter W T Pisters; George D Demetri; Murray F Brennan; Kouros Owzar
Journal:  Ann Surg       Date:  2013-09       Impact factor: 12.969

Review 3.  GISTogram: a graphic presentation of the growing GIST complexity.

Authors:  Riccardo Ricci; Angelo Paolo Dei Tos; Guido Rindi
Journal:  Virchows Arch       Date:  2013-08-23       Impact factor: 4.064

4.  Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy.

Authors:  Yoshitomo Yanagimoto; Tsuyoshi Takahashi; Kazuya Muguruma; Takahiro Toyokawa; Hiroshi Kusanagi; Takeshi Omori; Toru Masuzawa; Koji Tanaka; Seiichi Hirota; Toshirou Nishida
Journal:  Gastric Cancer       Date:  2014-05-23       Impact factor: 7.370

5.  PDL1 expression is an independent prognostic factor in localized GIST.

Authors:  François Bertucci; Pascal Finetti; Emilie Mamessier; Maria Abbondanza Pantaleo; Annalisa Astolfi; Jerzy Ostrowski; Daniel Birnbaum
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

6.  A CT-based nomogram for predicting the malignant potential of primary gastric gastrointestinal stromal tumors preoperatively.

Authors:  Chang Li; Wenhao Fu; Li Huang; Yingqian Chen; Pei Xiang; Jian Guan; Canhui Sun
Journal:  Abdom Radiol (NY)       Date:  2021-03-13

7.  Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Authors:  Christopher L Corless; Karla V Ballman; Cristina R Antonescu; Violetta Kolesnikova; Robert G Maki; Peter W T Pisters; Martin E Blackstein; Charles D Blanke; George D Demetri; Michael C Heinrich; Margaret von Mehren; Shreyaskumar Patel; Martin D McCarter; Kouros Owzar; Ronald P DeMatteo
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

Review 8.  Targeted therapy for cancer: the gastrointestinal stromal tumor model.

Authors:  Vinod P Balachandran; Ronald P Dematteo
Journal:  Surg Oncol Clin N Am       Date:  2013-07-24       Impact factor: 3.495

9.  Blood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor.

Authors:  Daniel R Perez; Raymond E Baser; Michael J Cavnar; Vinod P Balachandran; Cristina R Antonescu; William D Tap; Vivian E Strong; Murray F Brennan; Daniel G Coit; Samuel Singer; Ronald P Dematteo
Journal:  Ann Surg Oncol       Date:  2012-10-02       Impact factor: 5.344

10.  Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors.

Authors:  Piotr Rutkowski; Alessandro Gronchi
Journal:  Oncologist       Date:  2013-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.